Page 3 - ஜொல்லா சாள்க் நிறுவனம் க்கு உயிரியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜொல்லா சாள்க் நிறுவனம் க்கு உயிரியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜொல்லா சாள்க் நிறுவனம் க்கு உயிரியல் Today - Breaking & Trending Today

San Diego Community News Group - San Diego brewer marketer wins national award

Megan Stone with the ‘Woman of the Year’ Craft Beer Marketing Award. / Photo by Megan Stoneslideshow
San Diegan Megan Stone was honored at the Craft Beer Marketing Awards as the first recipient of the “Woman of the Year” award in 2020. Industry peers selected her for the award based on her experience as a brewer, marketer, social media influencer, and “diversity, equity and inclusion” advocate.
“I put these efforts in because it’s things that I care about and I don t necessarily sit there and think about how people think of me or how popular I am. It was just nice to know that people appreciated the work,” Stone said. “I think it s nice to have a woman of the year category because it shines the light on the different people that make up this industry.” ....

United States , San Diego , Jackie Dibella , Jim Mccune , U Laine Brew Co , Megan Stone , Year Craft Beer Marketing , Diegan Megan Stone , Craft Beer Marketing Awards , Dogfish Head Brewing , Modern Times , Laine Brew , ஒன்றுபட்டது மாநிலங்களில் , சான் டியாகோ , ஜாக்கி டிபெல்லா , ஜிம் ம்க்க்யூந் , உ லைன் கஷாயம் இணை , மேகன் ஸ்டோந் , ஆண்டு கைவினை பீர் சந்தைப்படுத்தல் , கைவினை பீர் சந்தைப்படுத்தல் விருதுகள் , நாய்மீன் தலை காய்ச்சுதல் , நவீன முறை , லைன் கஷாயம் ,

La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA (Angiotensin II) and XERAVA (Eravacycline) in Europe

La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA (Angiotensin II) and XERAVA (Eravacycline) in Europe
Warnings and Precautions
There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.
Adverse Reactions
The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.
Drug Interactions
Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. ....

United States , United Kingdom , Larry Edwards , Michael Hearne , Jim Phillips , Exchange Commission , Jolla Pharma , Jolla Pharmaceutical Company , Tetraphase Pharmaceuticals Inc , European Commission , Drug Administration , Jolla Pharmaceutical Company Nasdaq , European Economic Area , Chief Executive Officer , European Summary , Product Characteristics , Full Prescribing Information , Tetraphase Pharmaceuticals , Private Securities Litigation Reform Act , Financial Officer , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , லாரி எட்வர்ட்ஸ் , மைக்கேல் கேளுங்கள் , ஜிம் பிலிப்ஸ் , பரிமாற்றம் தரகு ,